Safety and feasibility evaluation of tourniquets for total knee replacement study
| ISRCTN | ISRCTN20873088 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN20873088 |
| Secondary identifying numbers | 20280 |
- Submission date
- 17/02/2016
- Registration date
- 17/02/2016
- Last edited
- 25/01/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
The majority of surgeons perform total knee replacement surgery with the aid of a tourniquet. The tourniquet interrupts the blood supply and drainage from the leg and helps to create a bloodless area for the surgery to take place. A tourniquet may however increase a patients’ risk of developing a blood clot. At the end of surgery the tourniquet is deflated and blood clots that may have accumulated in the leg are immediately free to flow (embolise) within the blood stream. In some cases, blood clots and debris can return to the heart where they are then free to travel to the brain. This risk has never been examined with any definitive clinical study and it’s not known if such a study would even be feasible. This is what this study is investigating.
Who can participate?
Adults about to have a total knee replacement at University Hospitals Coventry and Warwickshire NHS trust.
What does the study involve?
Participants are randomly allocated to one of two groups. Those in group 1 have their total knee replacement surgery with a tourniquet. Those in group 2 have their surgery without a tourniquet. They all have a magnetic resonance (MR) imaging scan of their brain before having surgery and afterwards to look for evidence of clots and debris in the brain. Some participants and surgeons taking part in the study are also invited to take part in an interview to discuss their views and opinions of the of the study and how acceptable they find it. Participants are also followed-up within a year of their surgery when they are asked about how much knee pain they are experiencing and the how well the replacement joint is functioning. The researchers involved in this study also collect data from an existing database of total knee replacement surgery in England and Wales (National Joint Registry-NJR) and map it to other existing databases of deaths and hospital reported blood clots.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
University Hospitals Coventry and Warwickshire NHS trust
When is the study starting and how long is it expected to run for?
January 2017 to June 2018
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
Mr Peter Wall
Contact information
Public
University of Warwick
Clinical Sciences Research Institute
Clinical Sciences Building
Clifford Bridge Road
Coventry
CV2 2DX
United Kingdom
 ORCID ID |
0000-0003-3149-3373 |
|---|
Study information
| Study design | Interventional and Observational; Design type: Treatment, Qualitative |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Other |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Safety and feasibility evaluation of tourniquets for Total Knee Replacement (SAFE-TKR): A pilot feasibility study |
| Study acronym | SAFE-TKR |
| Study objectives | Current study hypothesis as of 08/10/2018: This is a study designed to determine if a full randomised controlled trial comparing clinical outcomes following total knee replacement (TKR) surgery with or without a tourniquet is feasible Previous study hypothesis: This is a pilot trial investigating whether a full randomised controlled trial comparing the risk of blood clots developing after total knee replacement (TKR) surgery for patients that have a tourniquet applied during surgery verses those that do not is feasible. |
| Ethics approval(s) | West Midlands - Edgbaston Research Ethics Committee, 16/12/2015, ref: 15/WM/0455 |
| Health condition(s) or problem(s) studied | Topic: Musculoskeletal disorders, Surgery; Subtopic: Musculoskeletal (all Subtopics), Surgery; Disease: Elective Orthopaedic Surgery, All Surgery |
| Intervention | This feasibility study will comprise of three parts: 1. Patients due for TKR surgery will invited to take part in a pilot trial and randomised to surgery with or without a tourniquet with a view to recruiting 50 patients. All patients will undergo a Magnetic Resonance (MR) imaging scan of their brain before and after surgery to look for evidence of clots and debris in the brain. Other potentially important outcomes including knee pain and function within 12 months will also be collected. 2. Integrated qualitative research study. An interview study of around 30 patients and around 20 surgeons will capture the views and opinions of both groups regarding the acceptability of the pilot trial. 3. Retrospective multi-centre cohort study. A study of an existing database of TKR surgery in England and Wales (National Joint Registry-NJR) will be undertaken. The data will be mapped to other existing databases of deaths and hospital reported blood clots. |
| Intervention type | Other |
| Primary outcome measure | Primary outcome as of 04/05/2017: Total volume of acute brain lesions detected on Magnetic Resonance (MR) brain imaging per patient, day 1 or 2 post operatively. Original primary outcome: Total volume of acute brain lesions detected on Magnetic Resonance (MR) brain imaging per patient, day 1 post operatively |
| Secondary outcome measures | Current secondary outcome measures as of 08/10/2018: 1. Montreal Cognitive Assessment (MoCA) preoperatively and day 1, 2 and 7 days post operatively and 6 and 12 month post operatively. 2. Oxford Cognitive Screen (OCS) preoperatively and day 1, 2 and 7 post operatively 3. Mini-mental state examination (MMSE) scores preoperatively and on day 1, 2 and 7 post operatively 1. Knee pain is measured using the Oxford Knee Score post operatively at baseline, 1 week, 6 and 12 month 2. Thigh pain is measured using the Visual Analogue Score (VAS) for acute thigh pain at baseline, day 1, day 2 and 1 week 3. Knee pain is measured using the EQ-5D-5L at baseline, 1 week, 6 and 12 months 4. Number of symptomatic VTE events is measured by questionnaire up to 12 months post operatively 5. Surgical Complication rate is measured by questionnaire up to 12 month post operatively 6. Number of intra/post-operative blood transfusions are measured by patient notes up until discharge 7. Revision rate of the TKR prosthesis is measured by questionnaire or patient notes at 12 months 8. All-cause mortality rates are measured by patient notes or next of kin at 12 months 9. Change in haemoglobin concentration between pre-operative haemoglobin and post operative haemoglobin Previous secondary outcomes as of 04/05/2017: 1. Knee pain is measured using the Oxford Knee Score post operatively at baseline, 1 week, 6 and 12 month 2. Thigh pain is measured using the Visual Analogue Score (VAS) for acute thigh pain at baseline, day 1, day 2 and 1 week 3. Knee pain is measured using the EQ-5D-5L at baseline, 1 week, 6 and 12 months 4. Number of symptomatic VTE events is measured by questionnaire up to 12 months post operatively 5. Surgical Complication rate is measured by questionnaire up to 12 month post operatively 6. Number of intra/post-operative blood transfusions are measured by patient notes up until discharge 7. Revision rate of the TKR prosthesis is measured by questionnaire or patient notes at 12 months 8. All-cause mortality rates are measured by patient notes or next of kin at 12 months Original secondary outcomes: 1. Montreal Cognitive Assessment (MoCA) preoperatively and day 1, 2 and 7 post operatively 2. Oxford Cognitive Screen (OCS) preoperatively and day 1, 2 and 7 post operatively 3. Mini-mental state examination (MMSE) scores preoperatively and on day 1, 2 and 7 post operatively 4. Oxford knee score (OKS) preoperatively and at 6 and 12 months postoperatively 5. EuroQol (EQ-5D-5L) scores preoperatively and at 6 and 12 months postoperatively 6. Number of symptomatic VTE events up to 12 months postoperatively. 7. Type and frequency of all adverse and serious adverse events up to 12 months postoperatively 8. Number of intra/post-operative blood transfusions until discharge 9. Revision rate of the TKR prosthesis at 12 months 10. All cause mortality rates at 12 months |
| Overall study start date | 01/01/2016 |
| Completion date | 31/01/2019 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 50; UK Sample Size: 50 |
| Total final enrolment | 53 |
| Key inclusion criteria | Inclusion criteria as of 04/05/2017: 1. Patients must be aged 18 years and over 2. Patient is undergoing primary unilateral knee replacement 3. The patient is able to give written informed consent and participate fully in the trial interventions and follow up procedures Original inclusion criteria: 1. All patients undergoing an elective primary unilateral cemented total knee replacement (TKR) under the care of four orthopaedic consultants at University Hospitals Coventry and Warwickshire (UHCW) NHS trust 2. Male and Female 3. Lower age limit 18 years |
| Key exclusion criteria | Exclusion criteria as of 04/05/2017: 1. Patients for whom Magnetic Resonance (MR) imaging is contraindicated due to 1.1. None compliant heart pacemaker or defibrillator or 1.2. None compliant metallic foreign body e.g. in one or both eyes or aneurysm clips in the brain or 1.3. Claustrophobia (e.g. difficulty in an elevator or telephone box) 2. Patients not suitable for a thigh tourniquet (e.g. significant peripheral vascular disease) 3. Previous participation in the SAFE-TKR Trial Original exclusion criteria: 1. Patients who lack capacity under the Mental Capacity Act 2005 2. Patients for whom Magnetic Resonance (MR) imaging is either contraindicated (heart pacemaker, metallic foreign body in one or both eyes, or who have an aneurysm clip in their brain) or not feasible because of claustrophobia |
| Date of first enrolment | 07/04/2017 |
| Date of final enrolment | 01/03/2018 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Clinical Sciences Building
Clifford Bridge Road
Coventry
CV2 2DX
United Kingdom
Coventry, West Midlands
CV2 2DX
United Kingdom
Sponsor information
Hospital/treatment centre
Clinical Trials Unit
Warwick Medical School
Gibbet Hill Road
Coventry
CV4 7AL
England
United Kingdom
"ROR" |
https://ror.org/01a77tt86 |
|---|
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 31/12/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | The results of this research will be disseminated to the following groups: Patients and public. A public and patient workshop on the proposed research found consensus that the internet should be used whenever possible to disseminate the results. Led by a patient co-applicant and other PPI collaborators we will develop a study Facebook page and Twitter feed. These will track both the progress of the study and eventual results, and will allow people with an interest to have access to our findings in a contemporary and user-friendly way. Results will be presented in magazines such as Arthritis Today, and the study team will work with NHS Choices to prepare patient information for use after the pilot trial. Medical community. A large body of specialists including nurses, physiotherapists, occupational therapists, physicians, general practitioners, anaesthetists and orthopaedic surgeons typically manage patients before, during and after TKR surgery in secondary and tertiary care centres. These groups will be targeted through conferences, seminars and meetings. All key findings from the trial will be presented at national and international conferences such as the British Orthopaedic Association (BOA); British Association of Specialist Knee Surgeons (BASK) and American Academy of Orthopaedic Surgeons (AAOS). The annual conferences of the BOA and the AAOS have attendances of 1,600 and 32,000 surgeons respectively. The results of the research are likely to attract significant attention at meetings; particularly as the presentation of RCT evidence in this field is rare. Wider clinical community. The aim is to publish the protocol in the first year and publish the results in at least one major peer-reviewed publication by the end of the study. If a full trial is feasible the results are likely to attract significant attention. It is hoped that this research will assist NICE in updating the clinical pathway for VTE which includes guidance for elective hip and knee replacement surgery and the specific NICE clinical guideline “CG92 VTE: reducing the risk”. |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 10/04/2018 | 30/11/2020 | Yes | No |
| Results article | results | 22/01/2021 | 25/01/2021 | Yes | No |
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
25/01/2021: Publication reference added.
30/11/2020: Publication reference added.
12/05/2020: The following changes were made to the trial record:
1. The overall end date was changed from 31/12/2020 to 31/01/2019.
2. The total final enrolment was added.
08/10/2018: The following changes have been made to the trial record:
1. The study hypothesis has been updated
2. The secondary outcome measures have been updated
3. The recruitment end date has been changed from 01/08/2018 to 01/03/2018
04/05/2017: The inclusion and exclusion criteria and outcome measures have been updated. In addition, the recruitment start date has been updated from 01/02/2017 to 07/04/2017.
24/02/2016: Study status verified with principal investigator.
